Oppenheimer: Time To Buy Trillium Therapeutics

By: via Benzinga
In a report published Friday, Oppenheimer analysts initiated coverage ofTrillium Therapeutics Inc (NASDAQ: TRIL) with an Outperform ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.